HilleVax, a biotechnological firm previously in the spotlight for its experimental Norovirus vaccine, HIL-214, has made headlines again. After an extensive and ultimately disappointing Phase 2b trial in infants, the company is now strategizing a new target demographic: adults. Given the intricate
Despite tremendous advancements in medical science, drug discovery remains a daunting challenge, particularly when it comes to illnesses involving complex protein interactions. Conventional drug development strategies fall short when faced with the vast network of protein-protein interactions
As we witness a demanding push for the development of innovative asthma treatments, over 80 key companies globally have embarked on an ambitious journey. This initiative aims to create a robust arsenal of more than 90 therapeutic approaches, targeting a condition that continues to affect the
The partnership between Tetra Pharm Technologies and Kvantify signifies a major step forward in the realm of drug discovery, particularly within the arena of the endocannabinoid system (ECS). This alliance is poised to not only speed up the discovery process but also holds the promise of yielding
The financial markets have recently witnessed a significant uptick, particularly focusing on the robust performance of the S&P 500 index. With a history of early gains often translating into positive year-end outcomes, the current rise of over 10% within the first 100 trading days has set a hopeful
The biopharmaceutical industry is experiencing a profound transformation, marked by a wave of layoffs and strategic overhauls across companies of all sizes. Confronted with economic headwinds and the urgency to adapt, biopharma entities are taking decisive steps to shore up their operations. This
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
In a strategic move blending technological innovation with environmental consciousness, SGD Pharma has invested over €20 million to advance its facility in Zhanjiang, China. This significant refurbishment is not merely about upgrading the equipment but is part of a greener manifesto—committing to
The biotech startup Limula, founded in 2020, has announced the triumphant completion of a seed funding round, obtaining a significant $6.8 million. This investment is a clear indication of the potential seen in Limula's groundbreaking approach to cell and gene therapy. With such therapies typically
Engineered T-cell receptor (TCR) therapies hold a promising future in the realm of oncology, particularly for solid tumors—long considered a formidable adversary due to their complex microenvironment. In a strategic move, AmplifyBio and Xcell Biosciences have joined forces with a shared vision of
